Skip to main content
SpringerLink
Log in
Book cover

Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures pp 87–102Cite as

Anthracyclines and Anthracenediones

  • Chapter
  • First Online:

Part of the book series: Cancer Growth and Progression ((CAGP,volume 13))

Abstract

Daunorubicin was the first anthracycline isolated, a natural product isolated from the actinobacteria Streptomyces peucetius. It was identified in 1963 by both Italian and French groups [7, 38]. The Italian group focused on natural product analogues, and isolated doxorubicin from the S. peucetius caesius variant, and the French group produced semi-synthetic derivates [6]. Although a vast number of analogues were synthesized after these initial discoveries, only two other anthracyclines ever made it to market in most western countries and Japan, idarubicin and epirubicin. Several liposomal formulations have also been marketed.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Abdella BR, Fisher J (1985) A chemical perspective on the anthracycline antitumor antibiotics. Environ Health Perspect 64:4–18

    Article  CAS  PubMed  Google Scholar 

  2. Akman SA, Doroshow JH, Burke TG, Dizdaroglu M (1992) DNA base modifications induced in isolated human chromatin by NADH dehydrogenase-catalyzed reduction of doxorubicin. Biochemistry 31(13): 3500–3506

    Article  CAS  PubMed  Google Scholar 

  3. Alberts DS, Goldman R, Xu MJ, Dorr RT, Quinn J, Welch K et al (1996) Disposition and metabolism of topically administered alpha-tocopherol acetate: a common ingredient of commercially available sunscreens and cosmetics. Nutr Cancer 26(2):193–201

    Article  CAS  PubMed  Google Scholar 

  4. Alexopoulos A, Karamouzis MV, Stavrinides H, Ardavanis A, Kandilis K, Stavrakakis J et al (2004) Phase II study of pegylated liposomal doxorubicin (Caelyx) and docetaxel as first-line treatment in metastatic breast cancer. Ann Oncol 15(6):891–895

    Article  CAS  PubMed  Google Scholar 

  5. Altan N, Chen Y, Schindler M, Simon SM (1998) Defective acidification in human breast tumor cells and implications for chemotherapy. J Exp Med 187(10): 1583–1598

    Article  CAS  PubMed  Google Scholar 

  6. Arcamone F (1981) Doxorubicin: anticancer antibiotics. Academic, New York

    Google Scholar 

  7. Arcamone F, Cassinelli G, Fantini G, Grein A, Orezzi P, Pol C et al (1969) Adriamycin 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol Bioeng 11(6):1101–1110

    Article  CAS  PubMed  Google Scholar 

  8. Asbell MA, Schwartzbach E, Bullock FJ, Yesair DW (1972) Daunomycin and adriamycin metabolism via reductive glycosidic cleavage. J Pharmacol Exp Ther 182(1):63–69

    CAS  PubMed  Google Scholar 

  9. Awasthi S, Singhal SS, Srivastava SK, Zimniak P, Bajpai KK, Saxena M et al (1994) Adenosine triphosphate-dependent transport of doxorubicin, daunomycin, and vinblastine in human tissues by a mechanism distinct from the P-glycoprotein. J Clin Invest 93(3): 958–965

    Article  CAS  PubMed  Google Scholar 

  10. Bachur NR, Gordon SL, Gee MV (1978) A general mechanism for microsomal activation of quinone anticancer agents to free radicals. Cancer Res 38(6):1745–1750

    CAS  PubMed  Google Scholar 

  11. Bassan R, Lerede T, Borleri G, Chiodini B, Rossi A, Buelli M et al (2002) Phase I trial with escalating doses of idarubicin and multidrug resistance reversal by short-course cyclosporin A, sequential high-dose cytosine arabinoside, and granulocyte colony-stimulating factor for adult patients with refractory acute leukemia. Haematologica 87(3):257–263

    CAS  PubMed  Google Scholar 

  12. Beck WT, Danks MK, Wolverton JS, Chen M, Granzen B, Kim R et al (1994) Resistance of mammalian tumor cells to inhibitors of DNA topoisomerase II. Adv Pharmacol 29B:145–169

    Article  CAS  PubMed  Google Scholar 

  13. Benchekroun MN, Pourquier P, Schott B, Robert J (1993) Doxorubicin-induced lipid peroxidation and glutathione peroxidase activity in tumor cell lines selected for resistance to doxorubicin. Eur J Biochem 211(1–2): 141–146

    Article  CAS  PubMed  Google Scholar 

  14. Bertelli G, Gozza A, Forno GB, Vidili MG, Silvestro S, Venturini M et al (1995) Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol 13(11):2851–2855

    CAS  PubMed  Google Scholar 

  15. Bhalla K, Hindenburg A, Taub RN, Grant S (1985) Isolation and characterization of an anthracycline-resistant human leukemic cell line. Cancer Res 45(8): 3657–3662

    CAS  PubMed  Google Scholar 

  16. Billingham ME, Mason JW, Bristow MR, Daniels JR (1978) Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 62(6):865–872

    CAS  PubMed  Google Scholar 

  17. Bloomfield DJ, Krahn MD, Neogi T, Panzarella T, Smith TJ, Warde P et al (1998) Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points. J Clin Oncol 16(6):2272–2279

    CAS  PubMed  Google Scholar 

  18. Bristow MR, Minobe WA, Billingham ME, Marmor JB, Johnson GA, Ishimoto BM et al (1981) Anthracycline-associated cardiac and renal damage in rabbits. Evidence for mediation by vasoactive substances. Lab Invest 45(2):157–168

    CAS  PubMed  Google Scholar 

  19. Bristow MR, Thompson PD, Martin RP, Mason JW, Billingham ME, Harrison DC (1978) Early anthracycline cardiotoxicity. Am J Med 65(5):823–832

    Article  CAS  PubMed  Google Scholar 

  20. Bronchud MH, Howell A, Crowther D, Hopwood P, Souza L, Dexter TM (1989) The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer 60(1):121–125

    CAS  PubMed  Google Scholar 

  21. Camaggi CM, Comparsi R, Strocchi E, Testoni F, Angelelli B, Pannuti F (1988) Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. Cancer Chemother Pharmacol 21(3):221–228

    CAS  PubMed  Google Scholar 

  22. Camaggi CM, Strocchi E, Carisi P, Martoni A, Tononi A, Guaraldi M et al (1992) Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study. Cancer Chemother Pharmacol 30(4):307–316

    Article  CAS  PubMed  Google Scholar 

  23. Camaggi CM, Strocchi E, Martoni A, Angelelli B, Comparsi R, Pannuti F (1985) Epirubicin plasma and blood pharmacokinetics after single i.v. bolus in advanced cancer patients. Drugs Exp Clin Res 11(4):285–294

    CAS  PubMed  Google Scholar 

  24. Capranico G, Babudri N, Casciarri G, Dolzani L, Gambetta RA, Longoni E et al (1986) Lack of effect of glutathione depletion on cytotoxicity, mutagenicity and DNA damage produced by doxorubicin in cultured cells. Chem Biol Interact 57(2):189–201

    Article  CAS  PubMed  Google Scholar 

  25. Carmichael AJ, Riesz P (1985) Photoinduced reactions of anthraquinone antitumor agents with peptides and nucleic acid bases: an electron spin resonance and spin trapping study. Arch Biochem Biophys 237(2):433–444

    Article  CAS  PubMed  Google Scholar 

  26. Chabner B, Longo DL (2006) Cancer chemotherapy and biotherapy: principles and practice, 4th edn. Lippincott Williams & Wilkins, Philadelphia

    Google Scholar 

  27. Chabner BA, Fojo A (1989) Multidrug resistance: P-glycoprotein and its allies–the elusive foes. J Natl Cancer Inst 81(12):910–913

    Article  CAS  PubMed  Google Scholar 

  28. Chai M, Wientjes MG, Badalament RA, Burgers JK, Au JL (1994) Pharmacokinetics of intravesical doxorubicin in superficial bladder cancer patients. J Urol 152(2 Pt 1): 374–378

    CAS  PubMed  Google Scholar 

  29. Chiccarelli FS, Morrison JA, Cosulich DB, Perkinson NA, Ridge DN, Sum FW et al (1986) Identification of human urinary mitoxantrone metabolites. Cancer Res 46(9):4858–4861

    CAS  PubMed  Google Scholar 

  30. Cobleigh MA (1998) Hormone replacement therapy and nonhormonal control of menopausal symptoms in breast cancer survivors. Cancer Treat Res 94:209–230

    CAS  PubMed  Google Scholar 

  31. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC et al (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258(5088):1650–1654

    Article  CAS  PubMed  Google Scholar 

  32. Cottin Y, Touzery C, Dalloz F, Coudert B, Toubeau M, Riedinger A et al (1998) Comparison of epirubicin and doxorubicin cardiotoxicity induced by low doses: evolution of the diastolic and systolic parameters studied by radionuclide angiography. Clin Cardiol 21(9):665–670

    Article  CAS  PubMed  Google Scholar 

  33. Cummings J, Forrest GJ, Cunningham D, Gilchrist NL, Soukop M (1986) Influence of polysorbate 80 (Tween 80) and etoposide (VP-16–213) on the pharmacokinetics and urinary excretion of adriamycin and its metabolites in cancer patients. Cancer Chemother Pharmacol 17(1): 80–84

    Article  CAS  PubMed  Google Scholar 

  34. Dalton WS, Cress AE, Alberts DS, Trent JM (1988) Cytogenetic and phenotypic analysis of a human colon carcinoma cell line resistant to mitoxantrone. Cancer Res 48(7):1882–1888

    CAS  PubMed  Google Scholar 

  35. Deffie AM, Batra JK, Goldenberg GJ (1989) Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res 49(1):58–62

    CAS  PubMed  Google Scholar 

  36. Demicheli R, Bonciarelli G, Jirillo A, Foroni R, Petrosino L, Targa L et al (1985) Pharmacologic data and technical feasibility of intraperitoneal doxorubicin administration. Tumori 71(1):63–68

    CAS  PubMed  Google Scholar 

  37. Didolkar MS, Kanter PM, Baffi RR, Schwartz HS, Lopez R (1978) Comparison of regional versus systemic chemotherapy with adriamycin. Ann Surg 187(3): 332–336

    Article  CAS  PubMed  Google Scholar 

  38. Dimarco A, Gaetani M, Orezzi P, Scarpinato BM, Silvestrini R, Soldati M et al (1964) ‘Daunomycin’, a new antibiotic of the rhodomycin group. Nature 201: 706–707

    Article  CAS  PubMed  Google Scholar 

  39. Disa JJ, Chang RR, Mucci SJ, Goldberg NH (1998) Prevention of adriamycin-induced full-thickness skin loss using hyaluronidase infiltration. Plast Reconstr Surg 101(2):370–374

    Article  CAS  PubMed  Google Scholar 

  40. Dobbs NA, Twelves CJ (1998) What is the effect of adjusting epirubicin doses for body surface area? Br J Cancer 78(5):662–666

    CAS  PubMed  Google Scholar 

  41. Dobbs NA, Twelves CJ, Gillies H, James CA, Harper PG, Rubens RD (1995) Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry. Cancer Chemother Pharmacol 36(6):473–476

    Article  CAS  PubMed  Google Scholar 

  42. Doroshow J, Esworthy R, Chu F (1993) Structure and function of glutathione transferases. CRC, Boca Raton

    Google Scholar 

  43. Doroshow JH (1986) Role of hydrogen peroxide and hydroxyl radical formation in the killing of Ehrlich tumor cells by anticancer quinones. Proc Natl Acad Sci USA 83(12):4514–4518

    Article  CAS  PubMed  Google Scholar 

  44. Doroshow JH, Locker GY, Myers CE (1980) Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest 65(1):128–135

    Article  CAS  PubMed  Google Scholar 

  45. Dorr RT, Dordal MS, Koenig LM, Taylor CW, McCloskey TM (1989) High levels of doxorubicin in the tissues of a patient experiencing extravasation during a 4-day infusion. Cancer 64(12):2462–2464

    Article  CAS  PubMed  Google Scholar 

  46. Dresdale A, Bonow RO, Wesley R, Palmeri ST, Barr L, Mathison D et al (1983) Prospective evaluation of doxorubicin-induced cardiomyopathy resulting from postsurgical adjuvant treatment of patients with soft tissue sarcomas. Cancer 52(1):51–60

    Article  CAS  PubMed  Google Scholar 

  47. Duncan R (2007) Designing polymer conjugates as lysosomotropic nanomedicines. Biochem Soc Trans 35(Pt 1): 56–60

    CAS  PubMed  Google Scholar 

  48. Eijdems EW, Zaman GJ, de Haas M, Versantvoort CH, Flens MJ, Scheper RJ et al (1995) Altered MRP is associated with multidrug resistance and reduced drug accumulation in human SW-1573 cells. Br J Cancer 72(2):298–306

    Article  CAS  PubMed  Google Scholar 

  49. Eksborg S, Soderberg M, Nilsson B, Antila K (1990) Plasma pharmacokinetics of Idarubicin and its 13-hydroxymetabolite after intravenous and oral administration under fasting and non-fasting conditions. Acta Oncol 29(7):921–925

    Article  CAS  PubMed  Google Scholar 

  50. El-Saghir N, Otrock Z, Mufarrij A, Abou-Mourad Y, Salem Z, Shamseddine A et al (2004) Dexrazoxane for anthracycline extravasation and GM-CSF for skin ulceration and wound healing. Lancet Oncol 5(5):320–321

    Article  CAS  PubMed  Google Scholar 

  51. Endicott JA, Ling V (1989) The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58:137–171

    Article  CAS  PubMed  Google Scholar 

  52. Felsted RL, Richter DR, Bachur NR (1977) Rat liver aldehyde reductase. Biochem Pharmacol 26(12):1117–1124

    Article  CAS  PubMed  Google Scholar 

  53. Georges E, Sharom FJ, Ling V (1990) Multidrug resistance and chemosensitization: therapeutic implications for cancer chemotherapy. Adv Pharmacol 21:185–220

    Article  CAS  PubMed  Google Scholar 

  54. Gerweck LE, Kozin SV, Stocks SJ (1999) The pH partition theory predicts the accumulation and toxicity of doxorubicin in normal and low-pH-adapted cells. Br J Cancer 79(5–6):838–842

    Article  CAS  PubMed  Google Scholar 

  55. Ghalie RG, Edan G, Laurent M, Mauch E, Eisenman S, Hartung HP et al (2002) Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 59(6):909–913

    Article  CAS  PubMed  Google Scholar 

  56. Gianni L, Vigano L, Locatelli A, Capri G, Giani A, Tarenzi E et al (1997) Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 15(5):1906–1915

    CAS  PubMed  Google Scholar 

  57. Gil P, Favre R, Durand A, Iliadis A, Cano JP, Carcassonne Y (1983) Time dependency of adriamycin and adriamycinol kinetics. Cancer Chemother Pharmacol 10(2): 120–124

    Article  CAS  PubMed  Google Scholar 

  58. Goasguen JE, Dossot JM, Fardel O, Le Mee F, Le Gall E, Leblay R et al (1993) Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood 81(9):2394–2398

    CAS  PubMed  Google Scholar 

  59. Gonsette RE (2003) Mitoxantrone in progressive multiple sclerosis: when and how to treat? J Neurol Sci 206(2):203–208

    Article  CAS  PubMed  Google Scholar 

  60. Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385–427

    Article  CAS  PubMed  Google Scholar 

  61. Greene RF, Collins JM, Jenkins JF, Speyer JL, Myers CE (1983) Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols. Cancer Res 43(7): 3417–3421

    CAS  PubMed  Google Scholar 

  62. Grogan TM, Spier CM, Salmon SE, Matzner M, Rybski J, Weinstein RS et al (1993) P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 81(2):490–495

    CAS  PubMed  Google Scholar 

  63. Gros P, Ben Neriah YB, Croop JM, Housman DE (1986) Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 323(6090): 728–731

    Article  CAS  PubMed  Google Scholar 

  64. Harris RN, Doroshow JH (1985) Effect of doxorubicin-enhanced hydrogen peroxide and hydroxyl radical formation on calcium sequestration by cardiac sarcoplasmic reticulum. Biochem Biophys Res Commun 130(2): 739–745

    Article  CAS  PubMed  Google Scholar 

  65. Heinemann V, Murray D, Walters R, Meyn RE, Plunkett W (1988) Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine. Cancer Chemother Pharmacol 22(3):205–210

    Article  CAS  PubMed  Google Scholar 

  66. Heitmann C, Durmus C, Ingianni G (1998) Surgical management after doxorubicin and epirubicin extravasation. J Hand Surg [Br] 23(5):666–668

    CAS  Google Scholar 

  67. Hochster H, Liebes L, Wadler S, Oratz R, Wernz JC, Meyers M et al (1992) Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. J Natl Cancer Inst 84(22):1725–1730

    Article  CAS  PubMed  Google Scholar 

  68. Huffman DH, Bachur NR (1972) Daunorubicin metabolism in acute myelocytic leukemia. Blood 39(5): 637–643

    CAS  PubMed  Google Scholar 

  69. Hui YF, Cortes JE (2000) Palmar-plantar erythrodysesthesia syndrome associated with liposomal daunorubicin. Pharmacotherapy 20(10):1221–1223

    Article  CAS  PubMed  Google Scholar 

  70. Inaba M, Nagashima K, Sakurai Y (1984) Cross-resistance of vincristine-resistant sublines of P388 leukemia to mitoxantrone with special emphasis on the relationship between in vitro and in vivo cross-resistance. Gann 75(7):625–630

    CAS  PubMed  Google Scholar 

  71. Israel M, Pegg WJ, Wilkinson PM (1978) Urinary anthracycline metabolites from mice treated with adriamycin and N-trifluoroacetyladriamycin-14-valerate. J Pharmacol Exp Ther 204(3):696–701

    CAS  PubMed  Google Scholar 

  72. Jacquet JM, Bressolle F, Galtier M, Bourrier M, Donadio D, Jourdan J et al (1990) Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters. Cancer Chemother Pharmacol 27(3):219–225

    Article  CAS  PubMed  Google Scholar 

  73. Johnson RK, Zee-Cheng RK, Lee WW, Acton EM, Henry DW, Cheng CC (1979) Experimental antitumor activity of aminoanthraquinones. Cancer Treat Rep 63(3): 425–439

    CAS  PubMed  Google Scholar 

  74. Kalyanaraman B, Morehouse KM, Mason RP (1991) An electron paramagnetic resonance study of the interactions between the adriamycin semiquinone, hydrogen peroxide, iron-chelators, and radical scavengers. Arch Biochem Biophys 286(1):164–170

    Article  CAS  PubMed  Google Scholar 

  75. Kartner N, Riordan JR, Ling V (1983) Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 221(4617):1285–1288

    Article  CAS  PubMed  Google Scholar 

  76. Kozin SV, Gerweck LE (1998) Cytotoxicity of weak electrolytes after the adaptation of cells to low pH: role of the transmembrane pH gradient. Br J Cancer 77(10): 1580–1585

    CAS  PubMed  Google Scholar 

  77. Kremer LC, Caron HN (2004) Anthracycline cardiotoxicity in children. N Engl J Med 351(2):120–121

    Article  CAS  PubMed  Google Scholar 

  78. Kuhl JS, Krajewski S, Duran GE, Reed JC, Sikic BI (1997) Spontaneous overexpression of the long form of the Bcl-X protein in a highly resistant P388 leukaemia. Br J Cancer 75(2):268–274

    CAS  PubMed  Google Scholar 

  79. Lavie Y, Cao H, Volner A, Lucci A, Han TY, Geffen V et al (1997) Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. J Biol Chem 272(3):1682–1687

    Article  CAS  PubMed  Google Scholar 

  80. Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdivieso M et al (1982) Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 96(2):133–139

    CAS  PubMed  Google Scholar 

  81. Legha SS, Benjamin RS, Mackay B, Yap HY, Wallace S, Ewer M et al (1982) Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer. Cancer 49(9):1762–1766

    Article  CAS  PubMed  Google Scholar 

  82. Legrand O, Simonin G, Beauchamp-Nicoud A, Zittoun R, Marie JP (1999) Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. Blood 94(3):1046–1056

    CAS  PubMed  Google Scholar 

  83. Lemontt JF, Azzaria M, Gros P (1988) Increased mdr gene expression and decreased drug accumulation in multidrug-resistant human melanoma cells. Cancer Res 48(22):6348–6353

    CAS  PubMed  Google Scholar 

  84. Lipshultz SE, Lipsitz SR, Sallan SE, Simbre VC 2nd, Shaikh SL, Mone SM et al (2002) Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol 20(23):4517–4522

    Article  CAS  PubMed  Google Scholar 

  85. Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR et al (2004) The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 351(2): 145–153

    Article  CAS  PubMed  Google Scholar 

  86. List AF, Kopecky KJ, Willman CL, Head DR, Persons DL, Slovak ML et al (2001) Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 98(12):3212–3220

    Article  CAS  PubMed  Google Scholar 

  87. Lum BL, Fisher GA, Brophy NA, Yahanda AM, Adler KM, Kaubisch S et al (1993) Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. Cancer 72(11 Suppl):3502–3514

    Article  CAS  PubMed  Google Scholar 

  88. Marbeuf-Gueye C, Broxterman HJ, Dubru F, Priebe W, Garnier-Suillerot A (1998) Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells. Mol Pharmacol 53(1):141–147

    CAS  PubMed  Google Scholar 

  89. Marie JP (1995) P-glycoprotein in adult hematologic malignancies. Hematol Oncol Clin North Am 9(2): 239–249

    CAS  PubMed  Google Scholar 

  90. Marie JP, Faussat-Suberville AM, Zhou D, Zittoun R (1993) Daunorubicin uptake by leukemic cells: correlations with treatment outcome and mdr1 expression. Leukemia 7(6):825–831

    CAS  PubMed  Google Scholar 

  91. Marie JP, Zittoun R, Sikic BI (1991) Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 78(3):586–592

    CAS  PubMed  Google Scholar 

  92. Merlin JL, Guerci A, Marchal S, Missoum N, Ramacci C, Humbert JC et al (1994) Comparative evaluation of S9788, verapamil, and cyclosporine A in K562 human leukemia cell lines and in P-glycoprotein-expressing samples from patients with hematologic malignancies. Blood 84(1):262–269

    CAS  PubMed  Google Scholar 

  93. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE (1991) P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 9(1):17–24

    CAS  PubMed  Google Scholar 

  94. Moore MJ, Osoba D, Murphy K, Tannock IF, Armitage A, Findlay B et al (1994) Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol 12(4):689–694

    CAS  PubMed  Google Scholar 

  95. Moran E, Cleary I, Larkin AM, Amhlaoibh RN, Masterson A, Scheper RJ et al (1997) Co-expression of MDR-associated markers, including P-170, MRP and LRP and cytoskeletal proteins, in three resistant variants of the human ovarian carcinoma cell line OAW42. Eur J Cancer 33(4):652–660

    Article  CAS  PubMed  Google Scholar 

  96. Moreb JS, Oblon DJ (1992) Outcome of clinical congestive heart failure induced by anthracycline chemotherapy. Cancer 70(11):2637–2641

    Article  CAS  PubMed  Google Scholar 

  97. Mross K, Maessen P, van der Vijgh WJ, Bogdanowicz JF, Kurth KH, Pinedo HM (1987) Absorption of epi-doxorubicin after intravesical administration in patients with in situ transitional cell carcinoma of the bladder. Eur J Cancer Clin Oncol 23(5):505–508

    Article  CAS  PubMed  Google Scholar 

  98. Mross K, Maessen P, van der Vijgh WJ, Gall H, Boven E, Pinedo HM (1988) Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. J Clin Oncol 6(3):517–526

    CAS  PubMed  Google Scholar 

  99. Mulder HS, Dekker H, Pinedo HM, Lankelma J (1995) The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines with varying lipophilicity. Biochem Pharmacol 50(7):967–974

    Article  CAS  PubMed  Google Scholar 

  100. Muller I, Jenner A, Bruchelt G, Niethammer D, Halliwell B (1997) Effect of concentration on the cytotoxic mechanism of doxorubicin – apoptosis and oxidative DNA damage. Biochem Biophys Res Commun 230(2):254–257

    Article  CAS  PubMed  Google Scholar 

  101. Murdock KC, Child RG, Fabio PF, Angier RB, Wallace RE, Durr FE et al (1979) Antitumor agents. 1. 1,4-Bis[(aminoalkyl)amino]-9,10-anthracenediones. J Med Chem 22(9):1024–1030

    Article  CAS  PubMed  Google Scholar 

  102. Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, Young RC (1977) Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 197(4299):165–167

    Article  CAS  PubMed  Google Scholar 

  103. Nakagawa M, Schneider E, Dixon KH, Horton J, Kelley K, Morrow C et al (1992) Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells. Cancer Res 52(22):6175–6181

    CAS  PubMed  Google Scholar 

  104. Nakano E, Takeshige K, Toshima Y, Tokunaga K, Minakami S (1989) Oxidative damage in selenium deficient hearts on perfusion with adriamycin: protective role of glutathione peroxidase system. Cardiovasc Res 23(6):498–504

    Article  CAS  PubMed  Google Scholar 

  105. Noonan KE, Beck C, Holzmayer TA, Chin JE, Wunder JS, Andrulis IL et al (1990) Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 87(18):7160–7164

    Article  CAS  PubMed  Google Scholar 

  106. Ozols RF, Young RC, Speyer JL, Sugarbaker PH, Greene R, Jenkins J et al (1982) Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res 42(10): 4265–4269

    CAS  PubMed  Google Scholar 

  107. Patel S, Sprung AU, Keller BA, Heaton VJ, Fisher LM (1997) Identification of yeast DNA topoisomerase II mutants resistant to the antitumor drug doxorubicin: implications for the mechanisms of doxorubicin action and cytotoxicity. Mol Pharmacol 52(4):658–666

    CAS  PubMed  Google Scholar 

  108. Perez EA, Suman VJ, Davidson NE, Kaufman PA, Martino S, Dakhil SR et al (2004) Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. J Clin Oncol 22(18):3700–3704

    Article  CAS  PubMed  Google Scholar 

  109. Peterson C, Baurain R, Trouet A (1980) The mechanism for cellular uptake, storage and release of daunorubicin. Studies on fibroblasts in culture. Biochem Pharmacol 29(12):1687–1692

    Article  CAS  PubMed  Google Scholar 

  110. Peterson C, Trouet A (1978) Transport and storage of daunorubicin and doxorubicin in cultured fibroblasts. Cancer Res 38(12):4645–4649

    CAS  PubMed  Google Scholar 

  111. Piscitelli SC, Rodvold KA, Rushing DA, Tewksbury DA (1993) Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. Clin Pharmacol Ther 53(5):555–561

    Article  CAS  PubMed  Google Scholar 

  112. Plasschaert SL, van der Kolk DM, de Bont ES, Kamps WA, Morisaki K, Bates SE et al (2003) The role of breast cancer resistance protein in acute lymphoblastic leukemia. Clin Cancer Res 9(14):5171–5177

    CAS  PubMed  Google Scholar 

  113. Potmesil M, Kirschenbaum S, Israel M, Levin M, Khetarpal VK, Silber R (1983) Relationship of adriamycin concentrations to the DNA lesions induced in hypoxic and euoxic L1210 cells. Cancer Res 43(8):3528–3533

    CAS  PubMed  Google Scholar 

  114. Praet M, Laghmiche M, Pollakis G, Goormaghtigh E, Ruysschaert JM (1986) In vivo and in vitro modifications of the mitochondrial membrane induced by 4ʹ Epi-adriamycin. Biochem Pharmacol 35(17): 2923–2928

    Article  CAS  PubMed  Google Scholar 

  115. Raghunand N, He X, van Sluis R, Mahoney B, Baggett B, Taylor CW et al (1999) Enhancement of chemotherapy by manipulation of tumour pH. Br J Cancer 80(7):1005–1011

    Article  CAS  PubMed  Google Scholar 

  116. Rahman A, Goodman A, Foo W, Harvey J, Smith FP, Schein PS (1984) Clinical pharmacology of daunorubicin in phase I patients with solid tumors: development of an analytical methodology for daunorubicin and its metabolites. Semin Oncol 11(4 Suppl 3):36–44

    CAS  PubMed  Google Scholar 

  117. Raoul JL, Heresbach D, Bretagne JF, Ferrer DB, Duvauferrier R, Bourguet P et al (1992) Chemoemb olization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. Cancer 70(3):585–590

    Article  CAS  PubMed  Google Scholar 

  118. Reid JM, Pendergrass TW, Krailo MD, Hammond GD, Ames MM (1990) Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report. Cancer Res 50(20):6525–6528

    CAS  PubMed  Google Scholar 

  119. Robert J, Bui NB, Vrignaud P (1987) Pharmacokinetics of doxorubicin in sarcoma patients. Eur J Clin Pharmacol 31(6):695–699

    Article  CAS  PubMed  Google Scholar 

  120. Samuels BL, Murray JL, Cohen MB, Safa AR, Sinha BK, Townsend AJ et al (1991) Increased glutathione peroxidase activity in a human sarcoma cell line with inherent doxorubicin resistance. Cancer Res 51(2):521–527

    CAS  PubMed  Google Scholar 

  121. Satake S, Sugawara I, Watanabe M, Takami H (1997) Lack of a point mutation of human DNA topoisomerase II in multidrug-resistant anaplastic thyroid carcinoma cell lines. Cancer Lett 116(1):33–39

    Article  CAS  PubMed  Google Scholar 

  122. Savaraj N, Lu K, Manuel V, Loo TL (1982) Pharmacology of mitoxantrone in cancer patients. Cancer Chemother Pharmacol 8(1):113–117

    Article  CAS  PubMed  Google Scholar 

  123. Schneider E, Cowan KH, Bader H, Toomey S, Schwartz GN, Karp JE et al (1995) Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood 85(1):186–193

    CAS  PubMed  Google Scholar 

  124. Schneider E, Horton JK, Yang CH, Nakagawa M, Cowan KH (1994) Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res 54(1): 152–158

    CAS  PubMed  Google Scholar 

  125. Schott B, Robert J (1989) Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in culture. Biochem Pharmacol 38(22):4069–4074

    Article  CAS  PubMed  Google Scholar 

  126. Seymour LW, Ulbrich K, Strohalm J, Kopecek J, Duncan R (1990) The pharmacokinetics of polymer-bound adriamycin. Biochem Pharmacol 39(6):1125–1131

    Article  CAS  PubMed  Google Scholar 

  127. Shenkenberg TD, Von Hoff DD (1986) Mitoxantrone: a new anticancer drug with significant clinical activity. Ann Intern Med 105(1):67–81

    CAS  PubMed  Google Scholar 

  128. Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G (1997) Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 40 Suppl S13–19

    Article  CAS  PubMed  Google Scholar 

  129. Sinha BK, Katki AG, Batist G, Cowan KH, Myers CE (1987) Differential formation of hydroxyl radicals by adriamycin in sensitive and resistant MCF-7 human breast tumor cells: implications for the mechanism of action. Biochemistry 26(13):3776–3781

    Article  CAS  PubMed  Google Scholar 

  130. Slamon D, Leyland-Jones B, Shak S (1998) Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for markedly increased anticancer activity: a randomized, multinational controlled phase III trial. Proc Amer Soc Clin Oncol 17:98a

    Google Scholar 

  131. Smyth JF, Macpherson JS, Warrington PS, Leonard RC, Wolf CR (1986) The clinical pharmacology of mitozantrone. Cancer Chemother Pharmacol 17(2): 149–152

    Article  CAS  PubMed  Google Scholar 

  132. Sognier MA, Zhang Y, Eberle RL, Sweet KM, Altenberg GA, Belli JA (1994) Sequestration of doxorubicin in vesicles in a multidrug-resistant cell line (LZ-100). Biochem Pharmacol 48(2):391–401

    Article  CAS  PubMed  Google Scholar 

  133. Somlo G, Doroshow JH, Forman SJ, Leong LA, Margolin KA, Morgan RJ Jr et al (1994) High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of hope bone marrow oncology team. Cancer 73(6):1678–1685

    Article  CAS  PubMed  Google Scholar 

  134. Son YS, Suh JM, Ahn SH, Kim JC, Yi JY, Hur KC et al (1998) Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line. Cancer Chemother Pharmacol 41(5):353–360

    Article  CAS  PubMed  Google Scholar 

  135. Sonneveld P, Wassenaar HA, Nooter K (1984) Long persistence of doxorubicin in human skin after extravasation. Cancer Treat Rep 68(6):895–896

    CAS  PubMed  Google Scholar 

  136. Speechly-Dick ME, Owen ER (1988) Mitozantrone-induced onycholysis. Lancet 1(8577):113

    Article  CAS  PubMed  Google Scholar 

  137. Speth PA, Linssen PC, Holdrinet RS, Haanen C (1987) Plasma and cellular adriamycin concentrations in patients with myeloma treated with ninety-six-hour continuous infusion. Clin Pharmacol Ther 41(6):661–665

    Article  CAS  PubMed  Google Scholar 

  138. Speyer JL, Green MD, Kramer E, Rey M, Sanger J, Ward C et al (1988) Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 319(12):745–752

    Article  CAS  PubMed  Google Scholar 

  139. Stewart DJ, Grewaal D, Green RM, Verma S, Maroun JA, Redmond D et al (1991) Bioavailability and pharmacology of oral idarubicin. Cancer Chemother Pharmacol 27(4):308–314

    Article  CAS  PubMed  Google Scholar 

  140. Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D et al (1997) Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15(4):1318–1332

    CAS  PubMed  Google Scholar 

  141. Takanashi S, Bachur NR (1976) Adriamycin metabolism in man. Evidence from urinary metabolites. Drug Metab Dispos 4(1):79–87

    CAS  PubMed  Google Scholar 

  142. Tarasiuk J, Garnier-Suillerot A (1992) Kinetic parameters for the uptake of anthracycline by drug-resistant and drug-sensitive K562 cells. Eur J Biochem 204(2):693–698

    Article  CAS  PubMed  Google Scholar 

  143. Taylor SD, Davenport LD, Speranza MJ, Mullenbach GT, Lynch RE (1993) Glutathione peroxidase protects cultured mammalian cells from the toxicity of adriamycin and paraquat. Arch Biochem Biophys 305(2):600–605

    Article  CAS  PubMed  Google Scholar 

  144. Terasaki T, Iga T, Sugiyama Y, Hanano M (1982) Experimental evidence of characteristic tissue distribution of adriamycin. Tissue DNA concentration as a determinant. J Pharm Pharmacol 34(9):597–600

    CAS  PubMed  Google Scholar 

  145. Torti FM, Bristow MR, Howes AE, Aston D, Stockdale FE, Carter SK et al (1983) Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med 99(6): 745–749

    CAS  PubMed  Google Scholar 

  146. Twelves CJ, Dobbs NA, Aldhous M, Harper PG, Rubens RD, Richards MA (1991) Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer. Cancer Chemother Pharmacol 28(4):302–307

    CAS  PubMed  Google Scholar 

  147. Twelves CJ, Dobbs NA, Michael Y, Summers LA, Gregory W, Harper PG et al (1992) Clinical pharmacokinetics of epirubicin: the importance of liver biochemistry tests. Br J Cancer 66(4):765–769

    CAS  PubMed  Google Scholar 

  148. Unverferth DV, Unverferth BJ, Balcerzak SP, Bashore TA, Neidhart JA (1983) Cardiac evaluation of mitoxantrone. Cancer Treat Rep 67(4):343–350

    CAS  PubMed  Google Scholar 

  149. van Dalen EC, Michiels EM, Caron HN, Kremer LC (2006) Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev(4):CD005006

    Google Scholar 

  150. Vaupel PW, Frinak S, Bicher HI (1981) Heterogeneous oxygen partial pressure and pH distribution in C3H mouse mammary adenocarcinoma. Cancer Res 41(5):2008–2013

    CAS  PubMed  Google Scholar 

  151. Venturini M, Michelotti A, Del Mastro L, Gallo L, Carnino F, Garrone O et al (1996) Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol 14(12):3112–3120

    CAS  PubMed  Google Scholar 

  152. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M et al (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91(5):710–717

    Google Scholar 

  153. Von Hoff DD, Rozencweig M, Layard M, Slavik M, Muggia FM (1977) Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med 62(2):200–208

    Article  Google Scholar 

  154. Weenen H, van Maanen JM, de Planque MM, McVie JG, Pinedo HM (1984) Metabolism of 4ʹ-modified analogs of doxorubicin. unique glucuronidation pathway for 4ʹ-epidoxorubicin. Eur J Cancer Clin Oncol 20(7):919–926

    Article  CAS  PubMed  Google Scholar 

  155. Wishart GC, Bissett D, Paul J, Jodrell D, Harnett A, Habeshaw T et al (1994) Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial. J Clin Oncol 12(9):1771–1777

    CAS  PubMed  Google Scholar 

  156. Withoff S, Keith WN, Knol AJ, Coutts JC, Hoare SF, Mulder NH et al (1996) Selection of a subpopulation with fewer DNA topoisomerase II alpha gene copies in a doxorubicin-resistant cell line panel. Br J Cancer 74(4):502–507

    CAS  PubMed  Google Scholar 

  157. Yamamoto M, Maehara Y, Oda S, Ichiyoshi Y, Kusumoto T, Sugimachi K (1999) The p53 tumor suppressor gene in anticancer agent-induced apoptosis and chemosensitivity of human gastrointestinal cancer cell lines. Cancer Chemother Pharmacol 43(1):43–49

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. UCSD Department of Medicine, 9500 Gilman Drive, La Jolla, CA, 92093, USA

    Nicole Coufal & Lauge Farnaes

Authors
  1. Nicole Coufal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lauge Farnaes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicole Coufal .

Editor information

Editors and Affiliations

  1. Moores UCSD Cancer Center, 3855 Health Sciences Drive 0820, La Jolla, 92093-0820, California, USA

    Boris R. Minev

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media B.V.

About this chapter

Cite this chapter

Coufal, N., Farnaes, L. (2011). Anthracyclines and Anthracenediones. In: Minev, B. (eds) Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures. Cancer Growth and Progression, vol 13. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-9704-0_5

Download citation

  • DOI: https://doi.org/10.1007/978-90-481-9704-0_5

  • Published:

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-90-481-9703-3

  • Online ISBN: 978-90-481-9704-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation